Skip to content

Biolinq

4 viewers · 30d

Total raised

$90.0M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $90.0M
ROUNDS
1
INVESTORS
45
FOUNDED
N/A
HQ
San Diego, CA
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
4

AI overview

Updated

Biolinq Inc. is a pioneering healthcare technology company focused on enhancing metabolic health monitoring through innovative wearable biosensors. The company's flagship product, a continuous glucose monitoring (CGM) system, aims to provide a simpler and more accessible alternative to traditional glucose monitoring solutions, significantly improving the lives of people with diabetes.

What sets it apart

Biolinq stands out by offering a less invasive, needle-free continuous glucose monitoring solution that integrates real-time activity tracking, enhancing user experience and engagement.

Funding history

1 round
EquityMar 7, 2025
Form D
+$90.0M$90.0M total

Latest SEC filings

via EDGAR · CIK 0001685406
Form D · Mar 7, 2025View on EDGAR

Products

1 tracked

Continuous Glucose Monitoring System

Health Monitoring

Biolinq's continuous glucose monitoring system is a state-of-the-art wearable patch that harnesses the power of tiny electrochemical sensors to non-invasively measure glucose levels from the intradermal space beneath the skin. It provides users with real-time insights into their glucose levels while simultaneously monitoring their activity levels, all through a user-friendly interface.

  • Needle-free application for ease of use
  • Secure placement on the upper forearm for convenience
  • Real-time glucose monitoring for immediate awareness
  • Integrated activity tracking to contextualize glucose data